70 related articles for article (PubMed ID: 24378899)
1. Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer.
Song X; Liu J; Lu Y; Jin H; Huang D
Oncol Rep; 2014 Mar; 31(3):1191-8. PubMed ID: 24378899
[TBL] [Abstract][Full Text] [Related]
2. High Level of Adropin Promotes the Progression of Pancreatic Ductal Adenocarcinoma.
Hu J; Wu Q; Ding Q; Wu W; Li Q; Zheng Z
Curr Cancer Drug Targets; 2024; 24(6):629-641. PubMed ID: 37990897
[TBL] [Abstract][Full Text] [Related]
3. Radiation-induced alterations in immunogenicity of a murine pancreatic ductal adenocarcinoma cell line.
Schröter P; Hartmann L; Osen W; Baumann D; Offringa R; Eisel D; Debus J; Eichmüller SB; Rieken S
Sci Rep; 2020 Jan; 10(1):686. PubMed ID: 31959787
[TBL] [Abstract][Full Text] [Related]
4. Uridine-derived ribose fuels glucose-restricted pancreatic cancer.
Nwosu ZC; Ward MH; Sajjakulnukit P; Poudel P; Ragulan C; Kasperek S; Radyk M; Sutton D; Menjivar RE; Andren A; Apiz-Saab JJ; Tolstyka Z; Brown K; Lee HJ; Dzierozynski LN; He X; Ps H; Ugras J; Nyamundanda G; Zhang L; Halbrook CJ; Carpenter ES; Shi J; Shriver LP; Patti GJ; Muir A; Pasca di Magliano M; Sadanandam A; Lyssiotis CA
Nature; 2023 Jun; 618(7963):151-158. PubMed ID: 37198494
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
Soares KC; Rucki AA; Wu AA; Olino K; Xiao Q; Chai Y; Wamwea A; Bigelow E; Lutz E; Liu L; Yao S; Anders RA; Laheru D; Wolfgang CL; Edil BH; Schulick RD; Jaffee EM; Zheng L
J Immunother; 2015 Jan; 38(1):1-11. PubMed ID: 25415283
[TBL] [Abstract][Full Text] [Related]
6. Is programmed cell death ligand-1 expression required for optimal response to anti-PD-1 antibody in cancer.
Sendur MA; Aksoy S; Yildirim Ozdemir N; Akinci MB; Zengin N; Altundag K
J BUON; 2014; 19(2):577-8. PubMed ID: 24965426
[No Abstract] [Full Text] [Related]
7. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
Bryan LJ; Gordon LI
Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
[TBL] [Abstract][Full Text] [Related]
8. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
[TBL] [Abstract][Full Text] [Related]
9. Harnessing the immune system for cancer therapy.
Smith EL; Zamarin D; Lesokhin AM
Curr Opin Oncol; 2014 Nov; 26(6):600-7. PubMed ID: 25250678
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1-targeted therapies focusing on lymphatic malignancies: biological rationale, clinical challenges and opportunities.
Kedmi M; Avigdor A; Nagler A
Acta Haematol; 2015; 133(2):129-35. PubMed ID: 25247668
[TBL] [Abstract][Full Text] [Related]
11. B7-H1-expressing antigen-presenting cells mediate polarization of protumorigenic Th22 subsets.
Kuang DM; Xiao X; Zhao Q; Chen MM; Li XF; Liu RX; Wei Y; Ouyang FZ; Chen DP; Wu Y; Lao XM; Deng H; Zheng L
J Clin Invest; 2014 Oct; 124(10):4657-67. PubMed ID: 25244097
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.
Junttila TT; Li J; Johnston J; Hristopoulos M; Clark R; Ellerman D; Wang BE; Li Y; Mathieu M; Li G; Young J; Luis E; Lewis Phillips G; Stefanich E; Spiess C; Polson A; Irving B; Scheer JM; Junttila MR; Dennis MS; Kelley R; Totpal K; Ebens A
Cancer Res; 2014 Oct; 74(19):5561-71. PubMed ID: 25228655
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression in small cell neuroendocrine carcinomas.
Schultheis AM; Scheel AH; Ozretić L; George J; Thomas RK; Hagemann T; Zander T; Wolf J; Buettner R
Eur J Cancer; 2015 Feb; 51(3):421-6. PubMed ID: 25582496
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
Ritprajak P; Azuma M
Oral Oncol; 2015 Mar; 51(3):221-8. PubMed ID: 25500094
[TBL] [Abstract][Full Text] [Related]
15. CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression.
Viganò S; Banga R; Bellanger F; Pellaton C; Farina A; Comte D; Harari A; Perreau M
PLoS Pathog; 2014 Sep; 10(9):e1004380. PubMed ID: 25255144
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.
Lutz ER; Wu AA; Bigelow E; Sharma R; Mo G; Soares K; Solt S; Dorman A; Wamwea A; Yager A; Laheru D; Wolfgang CL; Wang J; Hruban RH; Anders RA; Jaffee EM; Zheng L
Cancer Immunol Res; 2014 Jul; 2(7):616-31. PubMed ID: 24942756
[TBL] [Abstract][Full Text] [Related]
17. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.
Motz GT; Santoro SP; Wang LP; Garrabrant T; Lastra RR; Hagemann IS; Lal P; Feldman MD; Benencia F; Coukos G
Nat Med; 2014 Jun; 20(6):607-15. PubMed ID: 24793239
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression in triple-negative breast cancer.
Mittendorf EA; Philips AV; Meric-Bernstam F; Qiao N; Wu Y; Harrington S; Su X; Wang Y; Gonzalez-Angulo AM; Akcakanat A; Chawla A; Curran M; Hwu P; Sharma P; Litton JK; Molldrem JJ; Alatrash G
Cancer Immunol Res; 2014 Apr; 2(4):361-70. PubMed ID: 24764583
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression is increased in a subset of basal type breast cancer cells.
Soliman H; Khalil F; Antonia S
PLoS One; 2014; 9(2):e88557. PubMed ID: 24551119
[TBL] [Abstract][Full Text] [Related]
20. Injury activated alveolar progenitors (IAAPs): the underdog of lung repair.
Chong L; Ahmadvand N; Noori A; Lv Y; Chen C; Bellusci S; Zhang JS
Cell Mol Life Sci; 2023 May; 80(6):145. PubMed ID: 37166489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
